The latest price target for ProPhase Labs (NASDAQ:PRPH) was reported by HC Wainwright & Co. on February 21, 2024. The analyst firm set a price target for $11.00 expecting PRPH to rise to within 12 months (a possible 1366.08% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for ProPhase Labs (NASDAQ:PRPH) was provided by HC Wainwright & Co., and ProPhase Labs reiterated their buy rating.

There is no last upgrade for ProPhase Labs

There is no last downgrade for ProPhase Labs.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProPhase Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProPhase Labs was filed on February 21, 2024 so you should expect the next rating to be made available sometime around February 21, 2025.

While ratings are subjective and will change, the latest ProPhase Labs (PRPH) rating was a reiterated with a price target of $11.00 to $11.00. The current price ProPhase Labs (PRPH) is trading at is $0.75, which is out of the analyst’s predicted range.